No price history available.
Key financial summary
Financials in MYR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | MYRm | 58 | 89 | 108 | 114 | 128 | 136 | N/A | N/A |
| Operating profit | MYRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | MYRm | 6 | 12 | 15 | 13 | 13 | 14 | N/A | N/A |
| EPS reported | MYR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | MYR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | MYR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | MYR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | MYRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | MYRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | MYRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | MYR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | MYR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in MYR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Optimax Holdings Berhad functions as an investment holding enterprise primarily dedicated to providing expert eye care services and related products across Malaysia. The firm's specialized clinics offer a comprehensive suite of treatments for various ocular conditions, including cataracts, glaucoma, dry eye syndrome, conjunctivitis, age-related macular degeneration, diabetic retinopathy, retinal detachment, pterygium, keratoconus, and ptosis, among other vision-related ailments. Beyond disease management, Optimax also performs refractive surgical procedures, comprehensive eye examinations, oculoplastic surgery, and provides consultation and dispensary services. In addition to its core medical offerings, the company is also involved in marketing food products. Its reach extends beyond national borders, serving an international clientele from countries such as Indonesia, the Philippines, Singapore, Thailand, Australia, China, Hong Kong, and Japan. Optimax Holdings Berhad was established in 1995 and its corporate headquarters are located in Kuala Lumpur, Malaysia.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Optimax Holdings Berhad functions as an investment holding enterprise primarily dedicated to providing expert eye care services and related products across Malaysia. The firm's specialized clinics offer a comprehensive suite of treatments for various ocular conditions, including cataracts, glaucoma, dry eye syndrome, conjunctivitis, age-related macular degeneration, diabetic retinopathy, retinal detachment, pterygium, keratoconus, and ptosis, among other vision-related ailments. Beyond disease management, Optimax also performs refractive surgical procedures, comprehensive eye examinations, oculoplastic surgery, and provides consultation and dispensary services. In addition to its core medical offerings, the company is also involved in marketing food products. Its reach extends beyond national borders, serving an international clientele from countries such as Indonesia, the Philippines, Singapore, Thailand, Australia, China, Hong Kong, and Japan. Optimax Holdings Berhad was established in 1995 and its corporate headquarters are located in Kuala Lumpur, Malaysia.